International News

Proposed Intellectual Property Agreement Between E.U., India Could Affect Generic Drug Exports, Advocacy Groups Say

February 10, 2012

The Independent examines how "[t]he cheap supply of antiretroviral drugs to people with AIDS across the world could be choked by an 'intellectual property' deal ... being negotiated [on Friday] at the 12th E.U.-India summit in New Delhi between the President of the European Commission, José Manuel Barroso, and the Indian Prime Minister Dr. Manmohan Singh."

AIDS advocacy and treatment organizations say the agreement will "hamper the export of these medicines to the developing world," while "E.U. trade commissioner, Karel De Gucht, has denied this, saying 'any agreement will have no impact on the right or the capacity of India to produce generic medicines,'" the Independent writes. The newspaper notes, "More than 80 percent of those on HIV treatment in developing countries are on generic medicines made in India" and "the country's generics industry is estimated at more than $20 billion (£12 billion), including exports, according to figures quoted in the Lancet last year" (Vallely, 2/10).

Back to other news for February 2012

This information was reprinted from with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.